Plasma pharmacokinetics of antimicrobial agents in critically Ill patients

Current Clinical Pharmacology

Volumn 8, Issue 1, 2013, Pages 5-12

  Pea, Federico ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Augmented renal clearance; Loading dose; Maintenance dose; Sepsis

Indexed keywords

ACICLOVIR; AMIKACIN; AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; ECHINOCANDIN; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; LINEZOLID; LIPOPEPTIDE; MACROLIDE; MEROPENEM; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TEICOPLANIN; TIGECYCLINE; VALGANCICLOVIR; VANCOMYCIN; VORICONAZOLE;

ANTIMICROBIAL THERAPY; ARTICLE; BURN; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MONITORING; HEALTH CARE SYSTEM; HUMAN; HYPOALBUMINEMIA; LEUKEMIA; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEPSIS; SEPTIC SHOCK; TRAUMATIC BRAIN INJURY; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84873143548     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488413804810585     Document Type: Article

References (54)

1. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-48.
2. Pea F, Viale P. Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? Crit Care 2009; 13: 214.
3. Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 2006; 42(Suppl 2): S72-81.
4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
5. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-34.
6. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50.
7. Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med 2010; 363: 689-91.
8. O'Brien JM Jr, Ali NA, Aberegg SK, et al. Sepsis. Am J Med 2007; 120: 1012-22.
9. Roberts JA, Taccone FS, Udy AA, et al. Vancomycin dosing in critically ill patients: robust methods for improved continuousinfusion regimens. Antimicrob Agents Chemother 2011; 55: 2704-9.
10. Mimoz O, Rolland D, Adoun M, et al. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med 2006; 32: 775-9.
11. Goncalves-Pereira J, Martins A, Povoa P. Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. Clin Microbiol Infect 2010; 16: 1258-63.
12. Taccone FS, Laterre PF, Spapen H, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14: R53.
13. Galvez R, Luengo C, Cornejo R, et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011; 38: 146-51.
14. Thallinger C, Buerger C, Plock N, et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008; 61: 173-6.
15. Barbour A, Schmidt S, Ma B, et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet 2009; 48: 575-84.
16. Pea F, Brollo L, Viale P, et al. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 2003; 51: 971-5.
17. Walraven CJ, North MS, Marr-Lyon L, et al. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011; 66: 2386-92.
18. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.
19. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
20. Ulldemolins M, Roberts JA, Wallis SC, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010; 65: 1771-8.
21. Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50: 99-110.
22. Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007; 60: 100-6.
23. Brink AJ, Richards GA, Schillack V, et al. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents 2009; 33: 432-6.
24. Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-11.
25. Lamoth F, Buclin T, Pascual A, et al. Imipenem underdosing as a cause of persistent neutropenic fever? J Antimicrob Chemother 2009; 64: 665-7.
26. Pea F, Furlanut M, Viale P. Is antimicrobial underexposure due to glomerular hyperfiltration a possible cause of increased mortality rate from bacterial infections in critically ill patients? Anaesth Intensive Care 2009; 37: 323-4.
27. Taccone FS, Laterre PF, Dugernier T, et al. Insufficient betalactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14: R126.
28. Udy AA, Varghese JM, Altukroni M, et al. Sub-therapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-9.
29. Baptista JP, Sousa E, Martins PJ, et al. Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents 2012; 39: 420-3.
30. Caldes A, Colom H, Armendariz Y, et al. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother 2009; 53: 4816-24.
31. Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011; 7: 539-43.
32. Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R, et al. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008; 36: 674-80.
33. Udy A, Boots R, Senthuran S, et al. Augmented creatinine clearance in traumatic brain injury. Anesth Analg 2010; 111: 1505-10.
34. Lamoth F, Buclin T, Csajka C, et al. Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother 2009; 53: 785-7.
35. Pea F, Viale P, Damiani D, et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother 2005; 49: 3550-3.
36. Conil JM, Georges B, Breden A, et al. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 2006; 28: 226-30.
37. Baptista JP, Udy AA, Sousa E, et al. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011; 15: R139.
38. Grootaert V, Willems L, Debaveye Y, et al. Augmented Renal Clearance in the Critically Ill: How to Assess Kidney Function. Ann Pharmacother 2012; 46: 952-9.
39. Udy AA, Roberts JA, De Waele JJ, et al. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012; 39: 455-7.
40. Gandhi TN, DePestel DD, Collins CD, et al. Managing antimicrobial resistance in intensive care units. Crit Care Med 2010; 38: S315-23.
41. Dryden M, Johnson AP, Ashiru-Oredope D, et al. Using antibiotics responsibly: right drug, right time, right dose, right duration. J Antimicrob Chemother 2011; 66: 2441-3.
42. Rea RS, Capitano B. Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 2007; 28: 596-603.
43. Rea RS, Capitano B, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30: 674-81.
44. Conil JM, Georges B, Ruiz S, et al. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 2011; 71: 61-71.
45. Pea F, Bertolissi M, Di Silvestre A, et al. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents 2002; 20: 326-32.
46. Vazquez M, Fagiolino P, Boronat A, et al. Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock. Int J Clin Pharmacol Ther 2008; 46: 140-5.
47. Pea F, Brollo L, Lugano M, et al. Therapeutic drug monitoringguided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Ther Drug Monit 2001; 23: 587-8.
48. Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010; 36: 332-9.
49. Blondiaux N, Wallet F, Favory R, et al. Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents 2010; 35: 500-3.
50. Roberts JA, Norris R, Paterson DL, et al. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012; 73: 27-36.
51. Pea F, Cojutti P, Sbrojavacca R, et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother 2011; 45: e37.
52. Taccone FS, Cotton F, Roisin S, et al. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56: 2129-31.
53. Alvarez-Lerma F, Grau S. Management of antimicrobial use in the intensive care unit. Drugs 2012; 72: 447-70.
54. Infectious Diseases Society of America. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081-3.